Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier.

blood-brain barrier blood-tumor barrier combination strategy glioblastoma intranasal drug delivery magnetic field nanoparticle ultrasound-wave

Journal

International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847

Informations de publication

Date de publication:
2024
Historique:
received: 05 12 2023
accepted: 22 02 2024
medline: 20 3 2024
pubmed: 20 3 2024
entrez: 20 3 2024
Statut: epublish

Résumé

The blood-brain barrier (BBB) and blood-tumor barrier (BTB) pose substantial challenges to efficacious drug delivery for glioblastoma multiforme (GBM), a primary brain tumor with poor prognosis. Nanoparticle-based combinational strategies have emerged as promising modalities to overcome these barriers and enhance drug penetration into the brain parenchyma. This review discusses various nanoparticle-based combinatorial approaches that combine nanoparticles with cell-based drug delivery, viral drug delivery, focused ultrasound, magnetic field, and intranasal drug delivery to enhance drug permeability across the BBB and BTB. Cell-based drug delivery involves using engineered cells as carriers for nanoparticles, taking advantage of their intrinsic migratory and homing capabilities to facilitate the transport of therapeutic payloads across BBB and BTB. Viral drug delivery uses engineered viral vectors to deliver therapeutic genes or payloads to specific cells within the GBM microenvironment. Focused ultrasound, coupled with microbubbles or nanoparticles, can temporarily disrupt the BBB to increase drug permeability. Magnetic field-guided drug delivery exploits magnetic nanoparticles to facilitate targeted drug delivery under an external magnetic field. Intranasal drug delivery offers a minimally invasive avenue to bypass the BBB and deliver therapeutic agents directly to the brain via olfactory and trigeminal pathways. By combining these strategies, synergistic effects can enhance drug delivery efficiency, improve therapeutic efficacy, and reduce off-target effects. Future research should focus on optimizing nanoparticle design, exploring new combination strategies, and advancing preclinical and clinical investigations to promote the translation of nanoparticle-based combination therapies for GBM.

Identifiants

pubmed: 38505170
doi: 10.2147/IJN.S450853
pii: 450853
pmc: PMC10949308
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2529-2552

Informations de copyright

© 2024 Lim et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Auteurs

Su Hyun Lim (SH)

Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, South Korea.
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, 21999, South Korea.

Gi Taek Yee (GT)

Department of Neurosurgery, Gil Medical Center, Gachon University, School of Medicine, Incheon, 21565, South Korea.

Dongwoo Khang (D)

Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, 21999, South Korea.
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, 21999, South Korea.
Department of Physiology, School of Medicine, Gachon University, Incheon, 21999, South Korea.

Classifications MeSH